GE HealthCare Technologies Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter J. Arduini
- Full Time Employees
- 54,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 500 West Monroe Street Chicago IL United States of America 60661
- IPO Date
- Dec 15, 2022
- CIK
- 0001932393
- Website
- gehealthcare.com
- Similar Companies
- Business
- GE HealthCare Technologies Inc. specializes in the design, production, and global distribution of advanced products, extensive services, and integrated digital platforms aimed at patient diagnostics, therapeutic interventions, and ongoing monitoring across numerous international regions. The organization structures its operations into four distinct divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division delivers sophisticated molecular imaging, computed tomography (CT), magnetic resonance (MR), image-guided therapy, and X-ray systems, alongside specialized offerings for women's health screening. The Ultrasound division offers solutions for the detection, assessment, treatment, and continuous oversight of various conditions through applications in radiology, primary care, cardiovascular health, women’s health, and handheld point-of-care devices, also incorporating surgical visualization and guidance products with AI-enabled productivity tools. The Patient Care Solutions division is dedicated to furnishing medical devices, essential consumables, supportive services, and intelligent digital tools for patient monitoring, anesthesia delivery and respiratory management, diagnostic cardiology, and maternal and infant care. The Pharmaceutical Diagnostics division supplies a range of diagnostic agents, including contrast media for CT, angiography, X-ray, and MR scans, as well as single-photon emission computed tomography and positron emission tomography, to the radiology and nuclear medicine sectors. This segment also provides pharmaceuticals administered prior to imaging to enhance tissue visibility and molecular imaging agents, which are radiopharmaceuticals with radioisotopes used for diagnostic scans. The company was established as a corporate entity in 2022 and maintains its primary corporate offices in Chicago, Illinois. In a significant recent development, the company has agreed to acquire Intelerad, a medical imaging software provider, for $2.3 billion, a move set to substantially enhance its cloud-based and AI-enabled imaging solutions, particularly expanding its reach into outpatient and teleradiology markets. This acquisition is expected to accelerate GE HealthCare's transition to a software-as-a-service (SaaS) business model and significantly boost its recurring revenue.
Company News
GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68
GE HealthCare Technologies Inc. $GEHC Stock Sold by Galvin Gaustad & Stein LLC
GE HealthCare to announce third quarter 2026 results on October 28, 2026
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, AppFolio, Delek US Holdings, Flutter Entertainment, Honeywell Aerospace, Intuitive Surgical, Marvell, NetApp, and More
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
GEHC vs. SYK: Which Stock Should Value Investors Buy Now?
GE HealthCare (GEHC) Upgraded to Buy: Here's Why
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GE HealthCare announces cash dividend increase for third quarter of 2026
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
GEHC or SYK: Which Is the Better Value Stock Right Now?